Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mass. Medicaid To Establish Quantity Limit For Short-Acting Beta-2 Agonists

Executive Summary

Massachusetts Medicaid will establish a quantity limit for short-acting beta-2 agonists to encourage physicians to alter "inadequate" anti-inflammatory therapy

You may also be interested in...



Mass. Medicaid Advises Against Zyprexa First Line, But No Prior Authorization

Massachusetts Medicaid is advising physicians against use of Lilly's atypical antipsychotic Zyprexa (olanzapine) as first-line therapy

Mass. Medicaid Leukotriene Blocker Limitation Seeks To Curb Allergy Use

Oral leukotriene blocker prescriptions will require prior authorization in the Massachusetts Medicaid program in an effort to curb use of the products for allergic rhinitis

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel